Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?
- 1 January 1998
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 47 (1) , 47-55
- https://doi.org/10.1023/a:1005824216444
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Transactivation Ability of p53 Transcriptional Activation Domain Is Directly Related to the Binding Affinity to TATA-binding ProteinJournal of Biological Chemistry, 1995
- Multifactorial analysis of p53 alteration in human cancer: A reviewInternational Journal of Cancer, 1994
- The Importance of p53 Gene Alterations in Human Cancer: Is There More Than Circumstantial Evidence?JNCI Journal of the National Cancer Institute, 1993
- p53-dependent apoptosis modulates the cytotoxicity of anticancer agentsCell, 1993
- p53 and c-erbB-2 Protein Expression in Breast Carcinomas: An Immunohistochemical Study Including Correlations with Receptor Status, Proliferation Markers, and Clinical Stage in Human Breast CancerAmerican Journal of Clinical Pathology, 1992
- Prognostic Factors and Treatment Decisions in Axillary-Node-Negative Breast CancerNew England Journal of Medicine, 1992
- p53: oncogene or anti-oncogene?Genes & Development, 1990
- Efficacy of Adjuvant Chemotherapy in High-Risk Node-Negative Breast CancerNew England Journal of Medicine, 1989
- A Randomized Clinical Trial Evaluating Sequential Methotrexate and Fluorouracil in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor-Negative TumorsNew England Journal of Medicine, 1989
- Histological Grading and Prognosis in Breast CancerBritish Journal of Cancer, 1957